^
    Evidence Level:
    Sensitive: C3 – Early Trials

    [PD-L1 expression-Merkel Cell Carcinoma-avelumab]

    Source:
    J Immunother Cancer
    Test:

    PD-L1 IHC 73-10 pharmDx

    Title:
    Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
    Published date:
    05/08/2020
    Excerpt:
    Median OS in patients with PD-L1+ (n=57) or PD-L1− (n=16) tumors was 12.9 months (95% CI 8.7 to 29.6 months) and 7.3 months (95% CI 3.4 to 14.0 months), respectively...
    DOI:
    10.1136/jitc-2020-000674